These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 30139272)

  • 1. Could combinations of new and old drugs enhance tumor cell death?
    Delou JM; Hajdu KL; Borges HL
    Future Oncol; 2018 Oct; 14(23):2319-2322. PubMed ID: 30139272
    [No Abstract]   [Full Text] [Related]  

  • 2. Difluoromethylornithine in cancer: new advances.
    Alexiou GA; Lianos GD; Ragos V; Galani V; Kyritsis AP
    Future Oncol; 2017 Apr; 13(9):809-819. PubMed ID: 28125906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A closer look at copanlisib.
    Dreyling M
    Clin Adv Hematol Oncol; 2018 Jan; 16(1):35-37. PubMed ID: 29741503
    [No Abstract]   [Full Text] [Related]  

  • 4. Cell death mechanisms of plant-derived anticancer drugs: beyond apoptosis.
    Gali-Muhtasib H; Hmadi R; Kareh M; Tohme R; Darwiche N
    Apoptosis; 2015 Dec; 20(12):1531-62. PubMed ID: 26362468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations.
    Broxterman HJ; Georgopapadakou NH
    Drug Resist Updat; 2005 Aug; 8(4):183-97. PubMed ID: 16154800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of early clinical trials of the combination of hydroxychloroquine with chemotherapy in cancer.
    Poklepovic A; Gewirtz DA
    Autophagy; 2014 Aug; 10(8):1478-80. PubMed ID: 24991829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editorial: Antitarget Therapies: New Frontiers in the Treatment of Cancer.
    Festuccia C; Lodola A; Gravina GL
    Anticancer Agents Med Chem; 2016; 16(1):4-6. PubMed ID: 26350030
    [No Abstract]   [Full Text] [Related]  

  • 8. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
    Carew JS; Giles FJ; Nawrocki ST
    Cancer Lett; 2008 Sep; 269(1):7-17. PubMed ID: 18462867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors.
    Ocaña A; Freedman O; Amir E; Seruga B; Pandiella A
    Cancer Metastasis Rev; 2014 Mar; 33(1):295-307. PubMed ID: 24338003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy.
    Pérez-Ruiz E; Etxeberria I; Rodriguez-Ruiz ME; Melero I
    Clin Cancer Res; 2017 Sep; 23(18):5326-5328. PubMed ID: 28790118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies for optimizing combinations of molecularly targeted anticancer agents.
    Dancey JE; Chen HX
    Nat Rev Drug Discov; 2006 Aug; 5(8):649-59. PubMed ID: 16883303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reanalysis of cancer drugs: old drugs, new tricks.
    Vande Woude GF; Kelloff GJ; Ruddon RW; Koo HM; Sigman CC; Barrett JC; Day RW; Dicker AP; Kerbel RS; Parkinson DR; Slichenmyer WJ
    Clin Cancer Res; 2004 Jun; 10(11):3897-907. PubMed ID: 15173099
    [No Abstract]   [Full Text] [Related]  

  • 13. [Combination phase I trials].
    Masuda N
    Gan To Kagaku Ryoho; 1996 Jan; 23(2):219-25. PubMed ID: 8611050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I studies of drug combinations.
    Verweij J; Disis ML; Cannistra SA
    J Clin Oncol; 2010 Oct; 28(30):4545-6. PubMed ID: 20855831
    [No Abstract]   [Full Text] [Related]  

  • 15. Advances in rational combination chemotherapy.
    Damon LE; Cadman EC
    Cancer Invest; 1986; 4(5):421-44. PubMed ID: 3542142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thinking Systematically About the Off-Label Use of Cancer Drugs and Combinations for Patients Who Have Exhausted Proven Therapies.
    Mailankody S; Prasad V
    Oncologist; 2016 Sep; 21(9):1031-2. PubMed ID: 27401893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone Deacetylase Inhibitors as Anticancer Drugs.
    Eckschlager T; Plch J; Stiborova M; Hrabeta J
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is cell death a critical end point for anticancer therapies or is cytostasis sufficient?
    Rixe O; Fojo T
    Clin Cancer Res; 2007 Dec; 13(24):7280-7. PubMed ID: 18094408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed emesis following anticancer chemotherapy.
    Kris MG; Roila F; De Mulder PH; Marty M
    Support Care Cancer; 1998 May; 6(3):228-32. PubMed ID: 9629874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drugs that lack single-agent activity: are they worth pursuing in combination?
    Gyawali B; Prasad V
    Nat Rev Clin Oncol; 2017 Apr; 14(4):193-194. PubMed ID: 28266519
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.